HM CINAC Comprehensive Neurosciences Centre
If you are the contact person for this centre and you wish to make any changes, please contact us.
Biomedical Engineer at the Integral Neurosciences Centre HM CINAC
Professor of Neurology at the Faculty of Medicine of the CEU San Pablo University and Director of the Centro Integral de Neurociencias HM CINAC
Neurologist specialising in Parkinson's disease at the Comprehensive Neuroscience Centre HM Cinac
A phase 2 clinical trial in France has examined whether taking an oral anti-diabetic drug called lixisenatide - a GLP1 receptor analogue, similar to those also used for weight loss - also has an effect on the progression of Parkinson's disease. The results indicate that there is a modest but significant decrease in the progression of motor symptoms of the disease, although side effects were also observed. The results are published in the journal NEJM.
Parkinson's disease is usually diagnosed when there is already extensive neuronal damage and symptoms are evident. Now, researchers at Cardiff University in the UK have used movement and sleep quality data from wearable accelerometers and concluded that they can help identify the disease early, years before clinical diagnosis. Although there is no effective preventive treatment, the authors propose that the tool can determine people at risk of developing Parkinson's disease and identify participants for clinical trials of neuroprotective treatments. The results are published in the journal Nature Medicine.